Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
10:21am, Monday, 29'th Jul 2024
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
07:30am, Friday, 26'th Jul 2024
Teva Pharmaceutical's stock is up 69% since December, driven by legal resolution, blockbuster drugs, debt reduction, and new product launches. Recent developments include the launch of biosimilars and
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
10:02am, Friday, 19'th Jul 2024
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
3 No-Brainer Stocks to Buy With $200 Right Now
05:21am, Wednesday, 17'th Jul 2024
There's never a bad time to put your money to work on Wall Street if you have a long-term mindset. A majority of online brokers have eliminated commission fees on common stock trades and minimum depos
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
01:21pm, Wednesday, 10'th Jul 2024
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
07:14am, Wednesday, 10'th Jul 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year.
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
06:00pm, Tuesday, 02'nd Jul 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesda
Teva's stock falls after report FTC has opened probe of patents
11:29am, Monday, 01'st Jul 2024
Teva Pharmaceuticals Industries Ltd.'s stock fell 2% Monday after a report said the Federal Trade Commission has opened an investigation into the Israeli generics company, citing its refusal to take d
FTC starts probe into Teva about some products' patents, Washington Post reports
10:12am, Monday, 01'st Jul 2024
The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
08:00am, Tuesday, 25'th Jun 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pe
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
11:40am, Monday, 24'th Jun 2024
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
09:50am, Monday, 24'th Jun 2024
PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Vic
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
05:35pm, Thursday, 13'th Jun 2024
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare
Teva Pharmaceutical: Buy This Bargain Before It's Gone
10:57am, Friday, 07'th Jun 2024
Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & John
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Tuesday, 04'th Jun 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annu
